INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm PR Newswire NEW YORK, May 15, 2020 NEW...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Stemline Therapeutics, Inc. PR Newswire NEW YORK, May 5, 2020 NEW YORK, May 5, 2020 /PRNewswire/ -- WeissLaw LLPย is investigating possible breaches of...
Moore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law Firm PR Newswire NEW YORK, May 5, 2020 NEW YORK, May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Stemline Therapeutics Inc. PR Newswire NEW YORK, May 4, 2020 NEW YORK, May 4, 2020 /PRNewswire/ --ย Rowley Law PLLC is investigating...
Stemline Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Stemline Therapeutics, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The...
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Stemline Therapeutics Inc. has obtained a Fair Price in its sale to Menarini Group PR Newswire MILWAUKEE, May 4, 2020 MILWAUKEE...
(STML) Alert: Johnson Fistel Investigates Proposed Sale of Stemline Therapeutics; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, May 4, 2020 SAN DIEGO, May 4, 2020 /PRNewswire/...
Acquisition of Stemline establishes Menariniโs presence in the U.S. biopharmaceutical oncology marketย Menarini will support further development of Stemlineโs ELZONRISยฎ and enable global...
Net revenue for ELZONRISยฎ was $11.8 million for the fourth quarterConference call and live webcast scheduled for Monday, March 16th, at 8:00 AM ET NEW YORK, March 13, 2020 (GLOBE NEWSWIRE...
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.